AbbVie

ABBV Healthcare & Pharma 4/10 Medium Risk
4/10
Sector avg: 2.8/10

AbbVie carries $64.5B in long-term debt, with $64.5B in scheduled principal maturities. DebtCanary scores ABBV at 4/10, indicating moderate refinancing pressure.

Maturity Schedule

Year 1 $6.0B Year 2 $5.1B Year 3 $4.5B Year 4 $8.6B Year 5 $1.0B Beyond 5 $39.3B
Period Amount Due % of Total
Year 1 (0-12 months) $6.0B 9.3%
Year 2 (12-24 months) $5.1B 8.0%
Year 3 (24-36 months) $4.5B 6.9%
Year 4 (36-48 months) $8.6B 13.4%
Year 5 (48-60 months) $1.0B 1.6%
Beyond 5 Years $39.3B 60.9%
Total Scheduled Maturities $64.5B 100.0%

Key Metrics

Total Long-Term Debt
$64.5B
Near-Term (12mo)
$6.0B
Interest Coverage
5.2x
Debt/Equity
N/A
Cash Coverage
0.87x
Operating Income
$15.1B

Score Components

Component Value Weight
Near-Term Maturity Concentration 9.3% 30%
Interest Coverage Ratio 5.2x 25%
Debt-to-Equity Ratio N/A 25%
Cash Coverage of Near-Term Debt 0.87x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-20. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for AbbVie →